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Abstract Francisella tularensis is a Gram-negative intracel-
lular bacterium that causes the disease tularemia. The disease
can be fatal if left untreated and there is currently no licenced
vaccine available; the identification of new therapeutic targets
is therefore required. Toll-like receptors represent an interest-
ing target for therapeutic modulation due to their essential role
in generating immune responses. In this study, we analysed
the in vitro expression of the key mitogen-activated protein
kinases (MAPKs) p38, JNK and ERK inmurine alveolar mac-
rophages during infection with F. tularensis. The phosphory-
lation profile of ERK highlighted its potential as a target for
therapeutic modulation and subsequently the effect of ERK
manipulation was measured in a lethal intranasal F. tularensis
in vivo model of infection. The selective ERK1/2 inhibitor
PD0325901 was administered orally to mice either pre- or
post-challenge with F. tularensis strain LVS. Both treatment
regimens selectively reduced ERK expression, but only the
pre-exposure treatment produced decreased bacterial burden
in the spleen and liver, which correlated with a significant
reduction in the pro-inflammatory cytokines IFN-γ, MCP-1,
IL-6, and TNF-α. However, no overall improvements in sur-
vival were observed for treated animals in this study. ERK
may represent a useful therapeutic target where selective
dampening of the immune response (to control the damaging
pathology seen during infection) is combined with antibiotic
treatment required to eradicate bacterial infection. This com-
bination treatment strategy has been shown to be effective in
other models of tularemia.
Introduction
Toll-like receptors (TLRs) are sentinels of the innate immune
system, functioning to detect invading microorganisms by
binding to pathogen-associated molecular patterns (PAMPs)
such as lipids, proteins and nucleic acids [1–3]. The binding
event triggers an intracellular signalling cascade through
dimerisation of the receptor and the subsequent recruitment
of signalling proteins, leading to the production of immune
mediators such as chemokines and cytokines. Eleven TLRs
have been identified in humans located on multiple cell types
including neutrophils, macrophages, and epithelial cells [4, 5].
TLR activity is vital for pathogen clearance, but dysregulation
can occur which can have severe consequences for the host.
Indeed, it is now well documented that an overactive immune
response can be more damaging to the host than the progres-
sion of infection by the pathogen [6]. This fine balance is
illustrated when a host is infected via the inhalational route
with the Gram-negative facultative intracellular bacterium
Francisella tularensis, where there is an initial suppression
of pro-inflammatory cytokines followed by a “cytokine
storm” prior to death [7].
The primary detection of F. tularensis was originally
thought to be mediated by TLR4 [8, 9]. However, more recent
studies demonstrate that it is likely that TLR2, and not TLR4,
confers the ability to detect F. tularensis [10–12]. TLR4 was
ruled out as a major receptor in the detection of F. tularensis as
TLR4-defective mice were no more susceptible to an inhala-
tional infection with F. tularensis than wild-type mice and the
survival rates were similar in both mouse strains [13]. In
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contrast, several studies have reported a requirement for TLR2
in the detection of F. tularensis following in vivo infection by
multiple challenge routes or in different types of cultured cell
[10, 14–19].More recently, the importance of TLR2-mediated
priming of the inflammasome to intracellular survival has
been highlighted [20]. Furthermore, a TLR2 deficiency en-
hanced murine susceptibility to pulmonary infection by the
F. tularensis live vaccine strain (LVS) and resulted in de-
creased production of pro-inflammatory cytokines including
TNF-α and IL-6 [10].
A number of studies have previously demonstrated the po-
tential therapeutic benefits of specifically targeting TLRs for
the treatment of infectious diseases including those caused by
Francisella sp. For example, bacterial DNA containing un-
methylated CpG motifs have been used to stimulate TLR9
and induce protection against subsequent challenge with the
intracellular pathogens F. tularensis strain LVS and Listeria
monocytogenes [21]. Furthermore, stimulation of TLR3 using
the synthetic dsRNA analogue poly(I:C) has been evaluated
for the treatment of F. tularensis strain LVS or strain SchuS4
infection in Balb/c mice [22]. Treatment as a monotherapy 1 h
prior to or 1 h after intranasal infection led to significant im-
provements in the survival of mice, correlating with an in-
creased influx of neutrophils to the lungs and early up-
regulation of cytokines IL-6, MCP-1, and TNF-α [22].
However, it is noteworthy that a combination therapy ap-
proach with the antibiotic levofloxacin was required for full
recovery.
In comparison to TLR receptors, less research has focused
on understanding the activation and phosphorylation states of
the downstream immune signalling cascade proteins during
F. tularensis infection and/or the potential for selectively
targeting these pathways with therapeutics. Previously, it has
been demonstrated that the up-regulation of p38, IkB and c-
Jun occurs following infection of murine macrophages with
F. tularensis strain LVS [15]. In addition, it has been demon-
strated that the uptake of Francisella novicida by macro-
phages is dependent upon ERK activation, and modulation
of the MAPK pathways is important for intracellular survival
of F. tularensis LVS [23, 24]. Furthermore, within an in-vivo
setting it was found that the inhibition of GSK3B (a serine/
threonine protein kinase) with lithium chloride significantly
reduces the production of pro-inflammatory cytokines such as
IFN-γ, IL-12p40, and TNF-α in F. tularensis LVS-infected
mice, and increases survival from 60 % in untreated mice to
90 % following treatment [25]. It is hypothesised that
targeting specific proteins within the TLR signalling cascades
may prevent the wide-ranging effects of direct TLR stimula-
tion. In this study we sought to determine the in vitro expres-
sion profile of key mitogen-activated protein kinases
(MAPKs) p38, JNK, and ERK following F. tularensis infec-
tion. Additionally, we determined the effect of inhibiting ERK
expression in vitro and in vivo during a F. tularensis infection.
Materials and methods
Preparation of bacteria
Francisella tularensis live vaccine strain (LVS) was grown
overnight on blood cysteine glucose agar (BCGA) plates in-
cubated at 37 °C, and used to inoculate 10ml PBS to anOD600
of 0.15 (∼1×109 CFU/ml). The resulting bacterial suspension
was diluted to the required inoculum. To confirm the CFU/ml
of the inoculum, serial dilutions were cultured on BCGA
plates for subsequent bacterial enumeration.
Infection of MH-S cell line with F. tularensis LVS
A continuous cell line of murine alveolar macrophages (MH-S
cells, ECACC UK) were seeded into 6-well plates (Corning,
US) at ∼4×105 cells/ml and incubated overnight at 37 °C to
allow the cells to adhere. Supernatants were then removed and
replaced with 1.5 ml of F. tularensis LVS inoculum to gener-
ate an MOI of 100. Plates were incubated at 37 °C for 2 h to
allow for internalisation of the bacteria, and then the superna-
tants were removed and replaced with 1.5 ml fresh media. The
plates were incubated at 37 °C and, at a range of timepoints,
supernatants were removed and stored at −20 °C for cytokine
analysis. The cells were washed once with chilled PBS and
then lysed by adding 350 μl PhosphoSafe™ extraction re-
agent (Merck, US) before incubating on ice for 5 min. Full
cell recovery was ensured by scraping wells with a rubber
policeman (Corning, US): 100 μl of the lysate was used for
bacterial enumeration, and a further 250 μl was centrifuged at
13,000 rpm for 5min to remove cell debris before being stored
at −20°C for analysis by western blotting.
In-vivo infection and treatment with ERK inhibitor
PD0325901
A total of 65 female 6- to 8-week-old Balb/c mice (Charles
River Laboratories, UK) were separated into four groups:
group I (20 mice), group II (20 mice), group III (15 mice)
and group IV (10 mice). All mice, except those in group IV,
were treated daily with either PBS or 0.05 μM PD0325901
(InvivoGen, France) by oral-gavage in a volume of 100 μl.
Groups I and II were treated from 24 h pre-infection, while
group III was treated from 48 h post-infection. The mice were
infected via the intranasal route with approximately
2.5×104 CFU of F. tularensis strain LVS. Scoring of the mice
occurred twice daily throughout the study. At 48 h and 96 h
post-challenge, five mice from each of groups I, II, III, and IV
were culled and the lungs, liver, and spleen were removed and
placed into aliquots of 2 ml PBS. Ten mice from each of
groups I, II, III, and IV were monitored for changes in surviv-
al. Organs were homogenised though a 0.2 μm cell sieve (BD
Biosciences) and screened for the levels of cytokines,
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activation of signalling proteins and bacterial enumeration on
agar. All animal studies were carried out in accordance with
the UK Scientific Procedures Act (1986). Animal handling
and infection procedures were carried out by trained staff at
Dstl.
Western blots
Proteins were separated on a 4-20 % tris-glycine polyacryl-
amide gel and then transferred onto Invitrolon™
polyvinylidene fluoride (PVDF) membranes (Invitrogen)
using a Novex® Semi-Dry Blotter (Invitrogen) according to
manufacturer’s instructions. The PVDFmembranes were then
incubated in blocking buffer (5 % [w/v] skimmed milk pow-
der and 0.1 % Tween® 20 (Sigma-Aldrich) dissolved in PBS)
for 2 h at room temperature. To detect ERK activation, the
membranes were washed in wash buffer (0.1 % Tween® 20 in
PBS) before being incubated overnight at 4 °C with the pri-
mary antibody [p38 - #9218; P-p38 - #9211; SAPK/JNK -
#9252; P-SAPK/JNK - #9251; ERK-1 - #4372; ERK-2 -
#9108; P-ERK-1/2 - #9101 (NEB)] at a dilution of 1:1,000
in blocking buffer. The membranes were then rinsed in wash
buffer and incubated for 1 h at room temperature with the
secondary antibody [goat anti-rabbit IgG conjugated to horse-
radish peroxidise (Bio-Rad)] at a dilution of 1:3,000 in
blocking buffer. The membranes were rinsed in wash buffer
and developed using enhanced chemiluminescence (ECL)-
Plus detection reagents (GE Healthcare) according to manu-
facturer’s instructions. The membranes were placed in a film
cassette and exposed to ECL hyperfilm (GE Healthcare)
which was allowed to air-dry before analysis by densitometry.
Cytometric bead array
The quantities of the cytokines IFN-γ, MCP-1, IL-6, IL-
12p70, IL-10, and TNF-α present within the lungs were mea-
sured using BD™ cytometric bead array (CBA) technology
(BD Biosciences) on a BD™ FACScan flow cytometer (BD
Biosciences) according to manufacturer’s instructions. A stan-
dard curve was generated and the concentration of each cyto-
kine was interpolated using GraphPad Prism® 5.01 software
(GraphPad). The levels of IL-12p70 and IL-10 were too low to
be detected, and so only the results of IFN-γ, MCP-1, IL-6,
and TNF-α are shown.
Statistical analysis
All transformations of data and statistical tests were performed
using GraphPad Prism® 5.01 software. Data from cytometric
bead arrays were analysed using PRISM, by fitting a quadratic
regression to the standard curves and reading the samples as
unknowns.
Results
ERK, p38, and JNK represent key signalling molecules in the
MAPK cascade [26]. Activation of these proteins, by phos-
phorylation, has diverse biological effects including cell pro-
liferation, apoptosis, and inflammation [27]. In this study,
temporal changes in the expression of total ERK, p38, and
JNK and the phosphorylated forms of the proteins produced
by in vitro cultured alveolar macrophage (MH-S) cell line in
response to infection with F. tularensis LVSwas measured via
western blot.
The in vitro expression of p38 remained constant during
the infection (Fig. 1a). However, there was a significant
change in the p38 activation profile. First, a rapid increase in
activation occurred immediately after the uptake of LVS; this
was a transient response, and the quantities of activated pro-
tein present returned to naïve levels by 0.5 h (Fig. 1b). After
the rapid and transient activation of p38 there was no re-
activation measured throughout the rest of the infection assay.
In comparison, limited in vitro activation of JNK proteins was
observed during the experiment, with the exception of the
24-h time point, where there was a decrease in the presence
of activated JNK-2/3 compared to that found at both 0.75 h
and 6 h (Fig. 2d). The expression of total JNK-2/3 remained
relatively constant (Fig. 2b), although there was a slight de-
crease in the expression of total JNK-1 from 6 to 24 h post-
uptake (Fig. 2a).
The in vitro expression of total ERK-1 and ERK-2 did not
alter significantly at any time point during the infection
(Fig. 3a, b). The activation profiles of the two proteins did,
however, display some interesting features (Fig. 3c, d). There
appeared to be two phases of protein activation, particularly
for ERK-2 (Fig. 3d). In the first hour after uptake a transient
activation was observed. However, from 1.5 h there was a
sustained activation of both ERK proteins which was main-
tained through to 6 h.
The interesting phosphorylation profile of ERK1/2 follow-
ing F. tularensis LVS infection in vitro led us to consider
modulation of the ERK proteins as an approach for treating
infection. An inhibitor of ERK PD0325901was identified and
assessed in vivo for its potential as a novel therapy.
PD0325901 is a small molecule inhibitor with specific activity
against phospho-ERK1/2 and increased potency compared to
its predecessors [28, 29]. First, we demonstrated that
PD0325901 was able to inhibit ERK expression during an in
vitro F. tularensismacrophage infection assay and that it had a
biological effect by significantly reducing the secretion of
TNF-α (data not shown).
Subsequently, the potential for ERK inhibition (using
PD0325901) was explored in vivo using a F. tularensis LVS
intranasal model of infection. Balb/C mice infected with
F. tularensis LVS showed a substantial increase in the level
of ERK activation between 48 h and 96 h, indicating the
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involvement of ERK phosphorylation during infection
in vivo, similarly to in vitro. Daily treatment of infected mice
with PD0325901 significantly reduced both ERK-1 and ERK-
2 activation in the lungs compared to PBS-treated mice at 96 h
(Fig. 4a, b). This was found for both the PD0325901 treatment
groups, irrespective of whether administration began at 24 h
pre-infection or at 48 h post-infection. However, unexpected-
ly, at 48 h PD0325901-treated mice appeared to show an in-
crease in ERK activation when compared to PBS-treated
mice.
To examine the effect of ERK inhibition on bacterial loads
in the organs of infected mice, bacterial enumeration was car-
ried out on samples taken from the lungs, liver, and spleens at
96 h post-infection (Fig. 5a). There was no significant differ-
ence in the numbers of bacteria present in the lungs of either of
the PD0325901-treated groups compared to PBS-treated con-
trols. However, there was a significant reduction in bacterial
burden in the liver and spleen of mice treated with
PD0325901 prior to infection when compared to PBS-
treated control mice. These differences in the spleen and liver
were not detected in mice treated with PD0325901 at 48 h
post-infection.
The effect of ERK inhibition on the inflammatory response
was examined by measuring the secretion of downstream in-
flammatory cytokines in the lungs, liver, and spleen of naïve,
PBS-treated or PD0325901-treated mice at 96 h after infection
(Fig. 5b-e). Measurable levels of IL-6 (Fig. 5b) MCP-1
(Fig. 5c), IFN-γ (Fig. 5d) and TNF-α (Fig. 5e) were detected,
but levels of IL-12p40 or IL-10 were below the limit of detec-
tion in all samples. At 96 h, no reduction in secretion of any of
the cytokines was found in the lungs, despite the observed
inhibition of ERK activation in the lungs of mice (Fig. 4).
Mice treated from 48 h post-infection with PD0325901
displayed a significant increase in IFN-γ and MCP-1 in livers
when compared to PBS-treated mice. The greatest effect of
ERK inhibition was observed in spleen samples, where there
was a significant decrease in the secreted levels of IFN-γ,
MCP-1, IL-6, and TNF-α in mice treated with PD0325901
prior to infection (at day −1) compared to PBS-treated con-
trols. This difference in the spleen was not seen when
PD0325901 was administered at 48 h post-infection. Despite
the PD0325901-associated inhibition of ERK activation with-
in the lungs and the reduced bacterial burdens in the spleens





















P-p38bFig. 1 The expression and the
levels of activated p38 in MH-S
cells throughout the course of a
F. tularensis LVS infection. The
expression of p38 (a) and the
levels of activated p38 (b) were
determined at several time points
after the 2-h uptake period.
Representative western blots are
shown below the corresponding
graphs. The experiment was
performed in triplicate (n= 3) and
each replicate was performed in
duplicate. Error bars show the
95 % confidence interval.
Significant difference from naïve
levels was determined by one-
way ANOVA and a Dunnett’s
multiple comparison post-test
(* = p < 0.05). Western blot
image: L —MagicMark™
ladder; N — naïve; +ve
— positive control
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in survival of PD0325901-treated groups compared to the
PBS-treated groups (Fig. 6).
Discussion
Antibiotics remain the most successful therapeutic regimen
for F. tularensis infection, although efficacy is dependent on
the correct administration of antibiotic in a timely manner
[30]. Aiding antibiotic efficiency through immune-
modulation is a strategy that is being explored for infectious
diseases.
In these studies, we have demonstrated that total expression
of the key MAPKs p38, JNK, and ERK were not significantly
altered in an in vitro macrophage model of F. tularensis LVS
infection. However, clear temporal changes in the phosphor-
ylated states of the MAPKs were identified. Notably, the in
vitro phosphorylation profile of ERK occurred in two distinct
peaks of activation within infected macrophages. In addition,
we identified that ERK was also significantly upregulated
in vivo following intranasal infection of mice with
F. tularensis LVS. By administering an inhibitor of ERK phos-
phorylation commencing both pre- and post-challenge, we
aimed to evaluate this as a therapeutic strategy for treating
infections caused by this organism. Following oral adminis-
tration of the inhibitor to mice, a reduction of ERK phosphor-
ylation was successfully achieved in vivo, with the greatest























Fig. 2 The expression and the
levels of activated JNK-1 and
JNK-2/3 in MH-S cells
throughout the course of a
F. tularensis LVS infection. The
expression of JNK-1 (a) and
JNK-2/3 (b) and the levels of
activated JNK-1 (c) and JNK-2/3
(d) were determined at several
time points after the 2-h uptake
period. Representative western
blots are shown below the
corresponding graphs. The
experiment was performed in
triplicate (n= 3) and each
replicate was performed in
duplicate. Error bars show the
95 % confidence interval.
Significant difference from naïve
levels was determined by one-
way ANOVA and a Dunnett’s
multiple comparison post-test
(* = p < 0.05). Western blot
image: L —MagicMark™
ladder; N — naïve; +ve —
positive control
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infection of mice. Treatment with the inhibitor resulted in
significant decreases in bacterial burden in the spleen and liver
but not at primary foci of infection of the lung. The reduction
in bacterial burden correlated with a significant decrease in the
pro-inflammatory cytokines IFN-γ, MCP-1, IL-6, and
TNF-α, although survival of infected mice was not improved
through administration of the inhibitor.
It has previously been reported that the activation of ERK
signalling occurs in response to F. tularensis infection in vitro
and in vivo [9, 19, 31]. Additionally, in vitro studies have

























Fig. 3 The expression and levels of activated ERK-1/2 in MH-S cells
throughout the course of a F. tularensis LVS infection. The expression of
ERK-1 (a) and ERK-2 (b) and the levels of activated ERK-1 (c) and
ERK-2 (d) were determined at several time points after the 2-h uptake
period. Representative western blots are shown below the corresponding
graphs. The experiment was performed in triplicate (n = 3) and each
replicate was performed in duplicate. Error bars show the 95 %
confidence interval. Significant difference from naïve levels was
determined by one-way ANOVA and a Dunnett’s multiple comparison
post-test (* = p< 0.05). Western blot image: L—MagicMark™ ladder;N
— naïve; +ve — positive control





















































































Fig. 4 The effect of PD0325901 treatment (0.05μM) on the activation of
ERK-1 and ERK-2 in the lungs of F. tularensis LVS infected Balb/c mice.
Groups of four mice infected via the intranasal route with
2.5 × 104 CFUF. tularensis LVS were treated daily with PBS from 24 h
pre-challenge (PBS), PD0325901 from 24 h pre-challenge [PD(−1)] or
from 48 h post-challenge [PD(+2)]. Naive mice were used as a control.
Detection of phosphorylated ERK-1 and ERK-2 in the lung homogenates
of Balb/c mice was carried out by western blotting. Significant difference
from PBS-treated group was determined using a one-tailed, unpaired t-






































































































Fig. 5 The effect of PD0325901
treatment (0.05 μM) on bacterial
burdens and cytokine secretion in
the organs of F. tularensis LVS-
infected Balb/c mice. Groups of
four mice infected via the
intranasal route with
2.5 × 104 CFUF. tularensis LVS
were treated daily with PBS from
24 h pre-challenge (PBS),
PD0325901 from 24 h pre-
challenge [PD(−1)]or from 48 h
post-challenge [PD(+2)]. Naive
mice were used as a control. On
day 4 post-challenge the organs
were removed, homogenised and
bacterial burdens were
determined (a). The homogenates
were also screened for the levels
of IL-6 (b), MCP-1 (c), IFN-γ
(d), and TNF-α (e). Significant
difference from PBS-treated
group was determined using a
one-tailed, unpaired t-test
(* = p < 0.05). Error bars show
95 % confidence intervals
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demonstrated that MAPK activation, including ERK activa-
tion, plays an important role in F. tularensis LVS infection-
induced apoptosis [32, 33]. To our knowledge, however, this
is the first assessment of manipulation of ERK as a possible
strategy for controlling F. tularensis infection. We found that
ERK signalling in the lungs of infectedmice could be success-
fully dampened by PD0325901 administration via oral ga-
vage. This did not result in a reduction in bacterial numbers
in the lungs (the site of bacterial infection), but there were
significantly reduced bacterial burdens in both the liver and
spleen of pre-treated mice. This may indicate that the prolif-
eration of the bacteria from the primary site of infection has
been reduced.
Sustained ERK activity promotes either intrinsic or extrin-
sic apoptotic pathways by induction of mitochondrial
Cytochrome C release or caspase-8 activation, permanent cell
cycle arrest, or autophagic vacuolisation [34]. Indeed, it has
been suggested that the rapid proliferation of Francisella co-
incides with the initial activation of the apoptotic signalling
pathway [35]. Therefore the relationship between ERK acti-
vation and the host mechanism of apoptosis could explain the
observed differences in bacterial burden and cytokine re-
sponse [33, 36]. In untreated F. tularensis infection (and in
this study, in PBS-treated mice), the replication of bacteria
within the lungs may induce apoptosis of infected cells such
as alveolar macrophages via ERK activation, releasing the
bacteria for proliferation throughout the host. In contrast, by
limiting the activation of ERK through the administration of
the inhibitor PD0325901, it is conceivable that the degree of
apoptosis could be reduced, preventing cellular release and dis-
semination of the bacteria. In this context, the lungs act as a trap,
with the result that bacterial burdens of this organ are unaffected
whereas secondary sites, such as the liver and spleen, demon-
strate reduced bacterial burdens as observed here. Further re-
search involving the in vivo administration for the inhibitor
and analysis of the presence/absence of apoptotic markers on
cellular surfaces is required in order to fully evaluate this hypoth-
esis, which was beyond the scope of this study.
In this study, ERK inhibition did not only alter bacte-
rial burden but also had a significant effect on the pro-
inflammatory secretion profile; specifically it was found
that IFN-γ, MCP-1, IL-6, and TNF-α were all reduced
in vivo following pre-treatment with PD0325901. It is
well documented that an inflammatory response is essen-
tial for pathogen clearance, although it is also clear that
pro-inflammatory responses contribute to the tissue dam-
age and pathology seen during infection [6]. Indeed, the
overactive immune response seen late during Francisella
infection has been hypothesised to be one of the main
contributors of detrimental outcome [7, 37]. Therefore,
in this context, the modulation of the immune response
achieved through inhibition of ERK with PD0325901
could be beneficial to survival of the host following in-
fection. However, in this study we demonstrated that al-
though dampening of ERK signalling was observed, along
with an associated reduction in cytokine secretion and a
decreased systemic proliferation of F. tularensis in treated
mice, ultimately there was no measurable improvement in
survival when compared to PBS-treated mice. This indi-
cates that ERK inhibition alone is not sufficient to im-
prove the outcome of infection with this pathogen.
However, it is possible that a combination therapy, for
example administering an ERK inhibitor with an antibiot-
ic, could demonstrate a more beneficial outcome of infec-
tion. The ERK inhibitor could be used in this context to
indirectly reduce systemic spread, whilst a bactericidal
antibiotic directly kills the bacteria that remain within
the lung. An analogous therapeutic strategy has already
been shown to be beneficial in our laboratory for the
treatment of the fully virulent SCHUS4 strain of
F. tularensis, whereby inhibition of HMGB1, combined
with levofloxacin use, significantly increased survival of
infected mice compared to controls [7]. In addition, relat-
ed approaches involving the administration of an antibiot-
ic and an immunodulating therapy have been reported for
other bacterial pathogens as well as in the treatment of
sepsis [38]. It is important to note that the data generated
in this study is derived from a murine model of tularemia
as the availability of clinical samples from human cases of
the disease is very limited, and it is not possible to con-
duct clinical trials in humans. However, it is well docu-
mented that there are similarities between human tulare-
mia and disease presentation within mouse models, which
are well accepted for research on F. tularensis [39, 40].
Therefore it is reasonable to extrapolate that targeting
















Fig. 6 The effect of PD0325901 treatment (0.05 μM) on survival of
Balb/c mice infected with F. tularensis LVS. Groups of four mice
infected via the intranasal route with 2.5 × 104 CFUF. tularensis LVS
were treated daily with PBS from 24 h pre-challenge (PBS),
PD0325901 from 24 h pre-challenge [PD(−1)] or from 48 h post-
challenge [PD(+2)]. Naive mice were used as a control. The animals
were scored daily and were culled upon reaching the humane endpoint
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highly conserved MAPKs in humans would likely have a
similar therapeutic benefit.
In conclusion, we have shown that PD0325901 can suc-
cessfully alter ERK activation during an in vivo F. tularensis
infection. It caused a reduction in bacterial burden in the liver
and spleen if given prior to infection, and also significantly
altered the host cytokine profile. The observed difference be-
tween mice given PD0325901 prior to or after infection is
probably due to the time the compound requires to take effect
in vivo and/or as a consequence of the bioavailability of the
compound. Ultimately, therapeutic manipulation of ERK did
not result in increased survival; however, it may be plausible
that PD0325901 and/or other ERK inhibitors would be suit-
able for assessment within models of infection in combination
with an anti-microbial therapy.
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